222results about How to "Prevent and reduce risk" patented technology

The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (N(t)RTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.

A topical otic composition containing an azalide antibiotic. A topical otic composition containing an azalide antibiotic and an medicament. A topical otic composition containing an azalide antibiotic and a polymer suspending agent. And methods for treating or preventing infections in the ear using azalide antibiotic compositions.

An implant for performing interbody fusion within a human spine, inserters for such an implant, and associated methodology. The implant is preferably formed in situ from at least two separate but lockable members (a base member and a closure member). The base member may be implanted into an interbody space first, after which the end plates may be finally prepared and the base member packed with fusion promoting substances before engaging and locking the closure member. The closure member provides structural support for the adjacent vertebral bodies (along with the base member) and may be selected after implantation of the base member having a specific length, width, height, taper, etc. . . . to ensure an optimal sizing of the implant for desired restoration of disc height, coronal taper, sagittal taper, etc. . . . .

The present invention relates to compositions comprising an anti-obesity agent and an anti-dyslipidemic agent useful for the treatment of dyslipidemia, dyslipidemia associated with obesity and dyslipidemia-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

This invention relates to the field of cardiac disease. More specifically, the invention relates to methods using an NGF antagonist for treating and preventing cardiac arrhythmia and methods of preventing death due to cardiac arrhythmia.

The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.

The Embodiments Disclosed Herein are Directed to Methods of preventing or reducing the risk or incidence of cancer in a tissue, gland, organ, or other cellular mass of a mammal by removing or destroying unwanted cells therefrom using compounds containing or based on peptides described herein.

Methods, compositions and kits are provided for effectively treating and preventing cancer metastasis in vivo and for increasing survival of subjects burdened with metastatic tumors by targeting a lysyl oxidase or its modulator, especially human lysyl oxidase. Also provided are methods for identifying lysyl oxidase inhibitors and the use of such inhibitors to prevent and treat tumors, particularly metastatic tumors, alone and in combination with chemotherapeutic agents. Further disclosed is the use of lysyl oxidase levels for measuring metastatic potential and survival.

The present invention provides a composition comprising a nicotine-containing material and an anti-cancer agent usable in the treatment and / or prevention or reduction of the risk of cancer and precancerous conditions as well as for preventing or reducing the risk of cancer recurrence. Furthermore, a composition comprising a nicotine-containing material and an anti-inflammatory agent usable in the treatment and / or prevention or reduction of the risk of inflammation, is provided. The nicotine containing composition can also include both an anti-cancer agent and an anti-inflammatory agent A device for administering the composition of the present invention to subjects can be a cigarette, smoking pipe, smokeless tobacco, electronic cigarette, transdermal patch or the like.

The present invention relates to the treatment of EE. More specifically, the invention relates to a new method of treating EE through the epicutaneous route. In particular, the method of the invention comprises applying to the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device and to a use of the skin patch device in the manufacture of a composition for treating eosinophilic esophagitis in a subject.

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

The disclosure relates to B-cell maturation antigen (BCMA), a receptor for APRIL and BAFF, and its use as an immunoregulatory agent in treatment of immunological disorders such as multiple sclerosis. The disclosure provides methods and compositions for treating neurodegenerative immunological disorders in mammals by administering soluble BCMA, an antibody against BCMA, or an antibody against a BCMA ligand, e.g., APRIL or BAFF.

The present application defines an antimicrobial composition comprising (a) at least two antimicrobial agents having different antimicrobial mechanisms of action and being present in amounts that together provide a synergistic antimicrobial effect or (b) an antimicrobial agent and a surface modifying agent, an antimicrobial masterbatch comprising antimicrobial composition (a) or (b) and a polymer carrier, an antimicrobial fibre composition comprising the antimicrobial masterbatch and a fibre substrate, an antimicrobial fibre comprising a fibre body or a fibre surface having the antimicrobial fibre composition, and a process for producing antimicrobial fibres.

There is provided methods, kits, combinations, and compositions comprising a Aspergillus oryzae protease enzyme, a Bacillus subtilis protease enzyme, and a Aspergillus niger lipase enzyme for treating a digestive disorder in a subject in need thereof. The methods, kits, combinations, and compositions may also be used along with an agent (or combination of agents) for raising the gastric pH, a digestive enzyme useful in enhancing digestive activity, a dietary supplement, or a pharmaceutical agent.

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

The present invention provides compounds and methods for the treatment, prevention, and / or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Method and apparatus for beverage extraction needle side holes or apertures. The leading and trailing edges of the apertures may be shaped or otherwise configured to help reduce the possibility of coring or shearing of material as the needle is inserted into and / or withdrawn from material, such as a cork. Convex leading and / or trailing edges may help deflect material away from the aperture, reducing shearing. Concave leading and / or trailing edges may help prevent entry of material into the aperture, again reducing shearing.

A control apparatus for a vehicular drive system including an electrically controlled differential portion having a differential mechanism, and an electric motor which is operatively connected to the differential mechanism and an operating state of which is controlled to control a differential state between input and output shaft speeds, and a transmission portion constituting a part of a power transmitting path between the differential portion and a vehicle drive wheel, the control apparatus including a differential-state switching portion for switching the differential portion between differential-state and non-differential states, a shifting control portion for controlling a shifting action of the transmission portion, and a learning control portion for effecting learning compensation of a control amount of a control element to be controlled during the shifting action, wherein the learning control portion includes a differential-state learning control portion operable to implement the learning compensation of the control amount of the control element when the shifting action takes place in the differential state of the differential portion, and a non-differential-state learning control portion operable to implement the learning compensation when the shifting action takes place in the non-differential state of the differential portion, and the shifting control portion controls the shifting action in a presently selected one of the differential and non-differential states of the differential portion, on the basis of the learning compensation implemented by one of the differential-state and non-differential-state learning control portions which is operable in the other of the differential and non-differential states of the differential portion.

A method and a system in an agricultural machine for the coordination of agricultural machines when refilling substance intended to be disseminated over an agricultural field by generating coordination data indicative of an optimum refill location, comprising a level sensor arranged for generating level data, said level data indicating a volume of a substance in a substance reservoir; a position sensor for generating and storing position data and storing or reading a preplanned route; a communication device arranged for transmitting and receiving data; characterised by: a coordination device generating coordination data, based on said level data, said preplanned route and said position data; and transmitting said generated coordination data via the communication device to a refill vehicle.

An image-forming apparatus is capable of performing a non-margin recording operation without a margin on a recording medium and providing a waiting time between a moment of termination of a movement of a carriage in one of opposite directions and a moment of initiation of a subsequent movement of the carriage in the other direction, if the non-margin recording operation is performed during the movement of the carriage in the above-indicated one direction. The carriage is moved in the other direction (returned) at a speed lower than that of the movement in the above-indicated one direction, so that the back surface of an edge portion (e.g., leading end portion) of the recording medium is protected from contamination with an ink mist produced from the ink droplets. The waiting time and the return speed of the carriage can be manually selected or changed by using an operator's control panel, so that the non-margin recording operation can be performed in a desired manner (in a high-image-quality mode or a high-speed mode).

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

The present invention relates to a method for the prognosis of bone metastasis in HER2+ breast cancer, which comprises determining if the MAF gene is amplified in a primary tumor sample. Likewise, the present invention also relates to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the MAF gene expression level, amplification or translocation. The present invention also relates to a method for predicting early bone metastasis in a subject suffering breast cancer. The present invention also relates to a c-Maf inhibitor as therapeutic agent for use in the treatment of HER2+ breast cancer metastasis. The present invention relates to kits for predicting bone metastasis and predicting the clinical outcome of a subject suffering from bone metastasis. Finally, the present invention relates to a method for typing of a subject suffering breast cancer and for classifying a subject from breast cancer into a cohort.

The electricity distribution network comprises a plurality of interconnection lines for the distribution of electricity among a plurality of interconnection boxes. At least some of said interconnection boxes are combined with a control unit for detection of stray voltage, comprising a transmitter to transmit to a receiver of at least one collecting unit a signal relating to any dispersion.

The present invention is generally related to a method of treating, preventing, or reducing the risk of developing type-2 diabetes, and, more particularly, is related to a method of administering a transdermal hydroalcoholic gel composition to treat or prevent type-2 diabetes and a method of administering a transdermal hydroalcoholic gel composition to increase glycemic control in a subject in need thereof.

The present invention provides methods of treating heart failure and improving renal function, and / or preventing the advancement of heart failure into advanced stages, and methods of counteracting ischemia due to a myocardial infarction by providing improved methods of administering a therapeutically effective amount CGRP as a controlled release formulation. The therapies can be administered on an outpatient or inpatient basis and can further be used as maintenance therapies.